WO2021167308A3 - 항암제 프로드러그 컨쥬게이트의 새로운 용도 - Google Patents
항암제 프로드러그 컨쥬게이트의 새로운 용도 Download PDFInfo
- Publication number
- WO2021167308A3 WO2021167308A3 PCT/KR2021/001925 KR2021001925W WO2021167308A3 WO 2021167308 A3 WO2021167308 A3 WO 2021167308A3 KR 2021001925 W KR2021001925 W KR 2021001925W WO 2021167308 A3 WO2021167308 A3 WO 2021167308A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prodrug conjugate
- anticancer agent
- novel use
- genotype
- agent prodrug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 난치성 암으로 알려진 KRAS 변이체 유전자형 또는 PTEN 단백질 소실 유전자형을 갖는 암에 대한 효과적인 치료를 위해, 알부민 결합 기능기(albumin binding moiety), 링커 및 항암 화학요법제를 포함하는 항함 화학요법제 프로드러그 컨쥬게이트를 포함하는 KRAS 변이체 또는 PTEN 단백질 소실 유전자형을 갖는 암 치료용 약학적 조성물을 제공한다.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200019242A KR102436012B1 (ko) | 2020-02-17 | 2020-02-17 | 항암제 프로드러그 컨쥬게이트의 새로운 용도 |
KR10-2020-0019242 | 2020-02-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021167308A2 WO2021167308A2 (ko) | 2021-08-26 |
WO2021167308A3 true WO2021167308A3 (ko) | 2021-10-14 |
Family
ID=77391020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/001925 WO2021167308A2 (ko) | 2020-02-17 | 2021-02-15 | 항암제 프로드러그 컨쥬게이트의 새로운 용도 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102436012B1 (ko) |
WO (1) | WO2021167308A2 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230085578A (ko) * | 2021-12-07 | 2023-06-14 | 한국과학기술연구원 | 암 예방 또는 치료를 위한 알부민 결합 전구약물, 이를 포함하는 약학 조성물 |
CN115715809A (zh) * | 2022-11-24 | 2023-02-28 | 武汉禾元生物科技股份有限公司 | 重组人血清白蛋白-药物偶联物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150023912A1 (en) * | 2012-02-21 | 2015-01-22 | Ktb Tumorforschungsgesellschaft Mbh | Combinations of albumin-based drug delivery systems |
KR20160060537A (ko) * | 2014-11-20 | 2016-05-30 | 파로스젠 주식회사 | 유도형질로 활성화되는 다기능성 항암제 전구체, 이의 제조방법 및 이의 용도 |
-
2020
- 2020-02-17 KR KR1020200019242A patent/KR102436012B1/ko active IP Right Grant
-
2021
- 2021-02-15 WO PCT/KR2021/001925 patent/WO2021167308A2/ko active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150023912A1 (en) * | 2012-02-21 | 2015-01-22 | Ktb Tumorforschungsgesellschaft Mbh | Combinations of albumin-based drug delivery systems |
KR20160060537A (ko) * | 2014-11-20 | 2016-05-30 | 파로스젠 주식회사 | 유도형질로 활성화되는 다기능성 항암제 전구체, 이의 제조방법 및 이의 용도 |
Non-Patent Citations (3)
Title |
---|
BEQUET-ROMERO M., DÍAZ Y.M., RAMÍREZ J.S., SELMAN-HOUSEIN K.-H., HERNÁNDEZ-BERNAL F., DE LA TORRE SANTOS A., PIÑERO J., BERMÚDEZ C: "Active immunotherapy with a VEGF targeted vaccine HeberSaVax: The road so far and the future ahead", ANNALS OF ONCOLOGY, KLUWER DORDRECHT, NL, vol. 29, 1 March 2018 (2018-03-01), NL , pages iii10, XP055855871, ISSN: 0923-7534, DOI: 10.1093/annonc/mdy047 * |
JUNG, SEONG U.: "Design and development of multi-targeted anticancer agents for anti-angiogenic therapy or tumor tissue-selective delivery", PH.D. THESIS, DEPT. OF PHARMACY, GRADUATE SCHOOL OF SEOUL NATIONAL UNIVERSITY, February 2015 (2015-02-01), pages 1 - 248, XP009530960 * |
PADAVANO JULIANNA, HENKHAUS REBECCA S., CHEN HWUDAURW, SKOVAN BETHANY A., CUI HAIYAN, IGNATENKO NATALIA A.: "Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer through GTPase Signaling Pathways", CANCER GROWTH AND METASTASIS 2017, vol. 8s1, 1 January 2015 (2015-01-01), pages CGM.S29407 - 1, XP055855870, ISSN: 1179-0644, DOI: 10.4137/CGM.S29407 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021167308A2 (ko) | 2021-08-26 |
KR102436012B1 (ko) | 2022-08-24 |
KR20210104463A (ko) | 2021-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shefet-Carasso et al. | Antibody-targeted drugs and drug resistance—challenges and solutions | |
WO2021167308A3 (ko) | 항암제 프로드러그 컨쥬게이트의 새로운 용도 | |
WO2022060836A8 (en) | Indole derivatives as ras inhibitors in the treatment of cancer | |
Sharma et al. | Recent advances in microbial toxin-related strategies to combat cancer | |
WO2020126609A3 (en) | Antibody drug conjugates (adc) containing saponin | |
MX2020012130A (es) | Proteinas multiespecificas de union de direccionamiento a anhidrasa carbonica 9 (caix), anoctamina-1 (ano1), mesotelina, antigeno de superficie celular de trofoblasto (trop2), antigeno carcinoembrionario (cea) o claudina-18.2. | |
WO2007033023A3 (en) | Compositions and methods for the diagnosis and therapy of bcl2-associated cancers | |
WO2004111192A3 (en) | Targeted delivery to legumain-expressing cells | |
WO2017210246A3 (en) | Penicillamine conjugates and particles and formulations thereof | |
MX2021011653A (es) | Composiciones inmunoterapeuticas y uso de las mismas. | |
WO2020225805A3 (en) | Precursor tri-specific antibody constructs and methods of use thereof | |
MX2019004963A (es) | Conjugados y particulas especificos del sstr y formulaciones de los mismos. | |
AU2021289730A8 (en) | BRM targeting compounds and associated methods of use | |
MX2022004989A (es) | Composiciones farmaceuticas de albumina y rapamicina. | |
WO2022235870A8 (en) | Ras inhibitors for the treatment of cancer | |
Zhang et al. | A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas | |
MX2023001648A (es) | Conjugado de anticuerpo y farmaco. | |
MX2023005301A (es) | Compuestos dirigidos a brm y metodos de uso asociados. | |
MX2023001788A (es) | Composiciones y metodos de enlazadores escindibles. | |
WO2003044161A3 (en) | Gene amplification and overexpression in cancer | |
WO2019125154A3 (en) | Transition metal-based functional moieties for preparing cell targeting conjugates | |
WO2020232191A8 (en) | Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer | |
EP0745390A3 (en) | Polymeric prodrugs for beta-lactamase and uses thereof | |
WO2022122765A3 (en) | Antibody and taxane combination therapy | |
AU2001279775A1 (en) | Medicament for the immunotherapy of malignant tumours |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21757873 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21757873 Country of ref document: EP Kind code of ref document: A2 |